Medifron DBT Co. Ltd

Medifron DBT Co. Ltd

065650 · KQ · Healthcare / Biotechnology

1,403.00KRW-27.00 (-1.89%)

Price History

Full chart

Market Stats

Previous Close1,430.00
Open1,416.00
Day Range1,391.00 – 1,441.00
52-Week Range1,326.00 – 7,840.00
Volume33.39K
Market Cap14.81B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.54
50-Day Avg1,637.56
200-Day Avg3,079.69

About

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents. In addition, it manufactures and supplies frozen and room temperature convenience food products, such as frozen sticky rice and fish cakes, tteokbokki sauce, and raw materials for sauce under the Memories of Elementary School Tteokbokki, Newtro, and K-TOWN brands. The company was formerly known as Medifron DBT Co., Ltd. and changed its name to Hyper Corporation Inc. in March 2024. Hyper Corporation Inc. was founded in 1997 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Dong-Bum Im
  • Employees44
  • HeadquartersCykan Holdings Tower, Seoul, South Korea, Korea
  • Websitehttps://www.hyper-corp.com

Leadership

  • Mr. Dong-Bum ImHead of Information Technology Department and Director · b. 1963

Financials

Income Statement

Currency: KRW2011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--5.41B8.22B13.10B20.91B19.89B17.41B31.41B49.25B45.29B42.88B58.46B76.19B
Growth (%)---+51.93%+59.42%+59.66%-4.88%-12.45%+80.41%+56.78%-8.04%-5.31%+36.33%+30.31%
Cost of Revenue--5.52B6.83B11.59B18.47B18.51B16.57B27.15B40.66B38.51B37.55B54.05B64.15B
Gross Profit---109.19M1.38B1.50B2.44B1.38B844.29M4.27B8.59B6.78B5.33B4.42B12.03B
Gross Margin---2.02%16.84%11.47%11.68%6.92%4.85%13.59%17.43%14.97%12.44%7.56%15.79%
Operating Expense--2.83B2.58B5.15B13.96B7.26B3.00B5.94B14.69B19.75B7.23B44.25B16.32B
Operating Income---2.94B-1.20B-3.64B-11.52B-5.88B-2.16B-1.67B-6.10B-12.97B-1.89B-39.83B-4.28B
Operating Margin---54.38%-14.62%-27.82%-55.08%-29.56%-12.41%-5.32%-12.38%-28.63%-4.42%-68.13%-5.62%
EBITDA-----------10.41B-985.04M-55.42B9.31B
EBITDA Margin-----------22.99%-2.30%-94.79%12.22%
Net Income---8.50B-1.71B-3.96B-11.45B-5.56B-1.78B-3.52B-6.76B-12.02B-1.96B-80.36B-315.64M
Net Income Margin---157.24%-20.79%-30.25%-54.77%-27.97%-10.22%-11.21%-13.72%-26.55%-4.57%-137.45%-0.41%
R&D--------631.39M356.97M1.61B660.79M390.95M436.53M
R&D as % of Total Revenue--------2.01%0.72%3.56%1.54%0.67%0.57%
Interest Expense000000001.56B413.97M708.59M656.48M54.33M6.84B
Interest Expense % of Total Revenue--0.00%0.00%0.00%0.00%0.00%0.00%4.97%0.84%1.56%1.53%0.09%8.97%

Balance Sheet

Currency: KRW2011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--26.48B30.84B27.75B26.24B21.57B19.46B47.22B49.10B55.75B55.79B60.40B71.94B
Total Liabilities--1.54B7.04B2.18B1.49B2.37B1.77B19.36B6.81B24.66B18.89B42.92B56.62B
Total Equity--24.94B23.80B25.57B24.75B19.20B17.69B27.86B42.29B31.09B36.89B17.49B15.35B
Cash--328.98M1.51B1.84B3.40B2.60B458.29M13.40B9.62B8.18B2.78B22.34M18.23B
Total Debt-------16.12M695.19M-----
Net Debt-----------1.43B6.89B18.08B

Cash Flow

Currency: KRW2011-12-312012-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow912.56M-1.32B701.96K-170.27M-1.15B-1.17B-852.48M-4.28B-1.67B-1.50B-2.91B-2.14B-4.54B-8.29B
Investing Cash Flow1.17B493.84M-273.71M-4.78B1.60B-8.29B-66.27M2.12B-15.88B-12.88B-19.03B-2.86B-50.27B-
Financing Cash Flow-2.20B26.65M5.98B5.98B10.80B10.80B27.43M26.65M26.93B10.60B20.53B-421.18M59.67B-
Capital Expenditure27.00M19.00M26.91M26.91M26.36M19.50M19.50M58.75M799.88M3.13B1.32B346.93M2.59B574.26M
Free Cash Flow--------4.73B-3.03B-4.67B-4.25B-2.50B-9.63B-8.87B
FCF to OCF-------110.41%181.14%310.95%145.86%117.04%212.37%106.93%

Earnings

Report DateMar 31, 2009Jun 30, 2009Dec 2, 2009Mar 3, 2010Jun 2, 2010Sep 1, 2010Dec 1, 2010Mar 2, 2011Jun 1, 2011Aug 31, 2011Nov 30, 2011Feb 29, 2012May 30, 2012Aug 29, 2012Nov 14, 2012Mar 15, 2013May 13, 2013Aug 13, 2013Nov 13, 2013Mar 28, 2014May 28, 2014Sep 3, 2014Dec 3, 2014Feb 25, 2015Jun 3, 2015Sep 2, 2015Dec 2, 2015Mar 2, 2016Jun 1, 2016Aug 31, 2016Nov 30, 2016Mar 1, 2017May 31, 2017Aug 30, 2017Nov 29, 2017Feb 28, 2018May 4, 2018Aug 13, 2018Nov 28, 2018Feb 27, 2019May 3, 2019Aug 12, 2019Nov 13, 2019Feb 17, 2020May 1, 2020Aug 18, 2020Nov 11, 2020Mar 26, 2021May 14, 2021Aug 17, 2021Nov 17, 2021May 6, 2022Aug 16, 2022Nov 14, 2022Mar 1, 2023May 15, 2023Aug 15, 2023Nov 13, 2023Mar 29, 2024May 13, 2024Aug 14, 2024Nov 14, 2024Mar 25, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---------------------------------------------------------------------
EPS Actual-324.82-241.06-319.00-124.20-316.75-581.12-607.60-310.5173.1238.0727.32288.26-275.44-635.50-13.95-13.41-10.09-4.11-14.18-50.86-272.49-254.23-450.64-4372.43-5.51-108.42-26.61-934.10-100.59-239.66-188.18-1807.79-54.66107.58117.55-6382.61-211.75-171.14-45.28-2595.35-172.30-304.18-307.26-183.07-120.08-464.05-818.18-142.7892.9877.8969.71-350.55-2035.00-529.65-1479.87-99.55-3468.7516.672636.66-2411.29-2868.470.47-8573.9971.74625.03-491.57-433.93-219.58-320.23
Surprise---------------------------------------------------------------------
Timing----------------After-hoursAfter-hoursAfter-hoursAfter-hours-------------------------------------------------

Key Statistics & Ratios

Market Cap14.81B
Enterprise Value29.61B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.17
Price / Book0.64
Revenue (TTM)84.86B
Gross Profit (TTM)13.31B
EBITDA-5.86B
Profit Margin-12.48%
Operating Margin-12.56%
Return on Equity-47.40%
Return on Assets-8.67%
Shares Outstanding10.93M
Shares Float30.89M
Beta1.54
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jun 9, 20261:2
  • Jun 26, 20251:8
  • Nov 8, 2017910:883